Review Article

A Comprehensive Review on Artificial Intelligence in Pharmaceutical Analytical Techniques: Advancements, Applications and Future Directions

Jawaharsamuvel R [*1], A R Sridevi [2], Swetha Sugunan Pallithara[3]

1. Assistant Professor, Department of Pharmaceutical Chemistry, College of Pharmacy, Sri Venkateswaraa University, Redhills, Chennai-600067, India.
2. Associate Professor, Department of Pharmacology, College of Pharmacy, Sri Venkateswaraa University, Redhills, Chennai-600067, India.
3. Assistant Professor, Department of Pharmaceutics, College of Pharmacy, Sri Venkateswaraa University, Redhills, Chennai-600067, India.

***Corresponding author's E-mail:** jawaharsam2606@gmail.com

Received: 02-07-2025; **Revised:** 28-09-2025; **Accepted:** 09-10-2025; **Published online:** 20-10-2025.

ABSTRACT

Artificial intelligence (AI) is increasingly redefining pharmaceutical analytical techniques by offering advanced solutions to manage complex datasets, improve accuracy, and enhance decision-making. This review highlights recent advancements, diverse applications, and emerging future directions of AI in pharmaceutical analysis. Conventional analytical methods such as chromatography, spectroscopy, and electrophoresis are reliable but often limited by their dependency on manual interpretation and lengthy experimental workflows. AI-driven tools, including machine learning (ML) and deep learning (DL) algorithms, provide enhanced capabilities for data processing, pattern recognition, and predictive modelling, thereby accelerating analysis and improving robustness. Applications of AI span across impurity profiling, dissolution testing, stability studies, and real-time quality monitoring, ensuring greater reliability in pharmaceutical development and manufacturing. Additionally, the integration of AI with chemometrics has led to breakthroughs in multivariate calibration, spectral deconvolution, and process analytical technologies (PAT). The review also discusses the role of AI in ensuring regulatory compliance through improved traceability, reproducibility, and automation of workflows. Future prospects include the development of explainable AI models, hybrid computational approaches, and integration with smart laboratories, enabling adaptive manufacturing and personalized medicine. While challenges such as data standardization, algorithm transparency, and regulatory acceptance remain, AI demonstrates significant potential to transform analytical science. Overall, this review underscores AI as a transformative force that bridges traditional pharmaceutical analysis with next-generation innovations, paving the way for more efficient, precise, and patient-centered drug development.

Keywords: Artificial Intelligence, Pharmaceutical Analytical Techniques, Machine Learning, Chemometrics, Process Analytical Technology.

INTRODUCTION

Background of Pharmaceutical Analytical Techniques

Pharmaceutical analytical techniques form the bedrock of drug discovery, development, manufacturing, and quality control. These methodologies ensure the identity, purity, potency, and stability of pharmaceutical products, directly impacting patient safety and therapeutic efficacy. Traditional analytical approaches, such as chromatography, spectroscopy, and electrochemistry, have been meticulously refined over decades, establishing robust frameworks for characterization and quantification. High-performance liquid chromatography (HPLC), for instance, has become indispensable for separating and quantifying components in complex mixtures, while mass spectrometry (MS) offers unparalleled sensitivity for molecular identification[1]. Nuclear Magnetic Resonance (NMR) spectroscopy provides detailed structural information, and various spectroscopic methods like UV-Vis and IR are vital for routine quality assessments[2]. The precise application of these techniques underpins regulatory compliance and facilitates the progression of drug candidates through clinical trials. Analytical methods in pharmaceuticals are not static; they continuously evolve to meet the challenges posed by novel drug modalities, complex formulations, and the increasing demand for faster, more efficient, and cost-effective analyses[3].

Emergence of Artificial Intelligence in Pharmaceutical Sciences

The digital transformation across scientific disciplines has introduced Artificial Intelligence (AI) as a powerful computational paradigm, extending its influence into pharmaceutical sciences[4, 5]. AI encompasses various computational techniques that enable machines to simulate human cognitive functions, including learning, problem-solving, and decision-making[6, 7]. Its applications span drug discovery, clinical trials, and manufacturing, providing a mechanism to process and interpret vast[8], complex datasets[1, 9]. The pharmaceutical industry, with its extensive data generation from research, development, and production, finds AI particularly compelling for extracting meaningful insights and automating intricate processes[1, 10]. The adoption of AI is driven by the potential to accelerate drug development timelines, reduce costs, and enhance the precision of various operations[1]. AI techniques, including machine learning and deep learning, are adept at identifying patterns and making predictions from large volumes of data, which aligns well with the data-intensive nature of pharmaceutical analysis[10].

Objectives and Scope of the Review

This review systematically evaluates the integration and influence of Artificial Intelligence within modern pharmaceutical analytical techniques. It seeks to provide a comprehensive overview of how AI methodologies are transforming established analytical practices, enhancing data interpretation, and streamlining workflows in pharmaceutical research and quality control. The review categorizes AI applications across various analytical platforms, offering specific examples of their implementation and impact. It further examines the benefits, such as improved efficiency, accuracy, and predictive capabilities, while also addressing the inherent challenges, including data quality, model interpretability, and regulatory compliance. Moreover, this discussion forecasts future trajectories for AI integration, considering emerging technologies and their implications for personalized medicine and autonomous laboratory operations. The scope encompasses a detailed exploration of AI's foundational concepts, its specific applications in techniques like HPLC, MS, and NMR, its role in quality control and process analytical technology, and the overarching regulatory and ethical considerations.

Foundations of Artificial Intelligence and Machine Learning in Pharmaceutical Analysis

Definitions and Core Concepts

Artificial Intelligence (AI) broadly refers to the development of computer systems capable of performing tasks that typically require human intelligence, such as learning, decision-making, and problem-solving[11]. Within AI, Machine Learning (ML) constitutes a significant subset[5], enabling systems to learn from data without explicit programming[10, 8]. ML algorithms identify patterns and build models based on training data, subsequently using these models to make predictions or decisions on new, unseen data[7]. Key ML concepts include supervised learning, where models are trained on labeled datasets, and unsupervised learning, which identifies patterns in unlabeled data[13]. Reinforcement learning, another paradigm, involves agents learning optimal actions through trial and error within an environment[14]. These core concepts provide the theoretical underpinnings for AI's utility in analyzing complex pharmaceutical data, from spectroscopic fingerprints to chromatographic profiles, by discerning subtle correlations that might elude traditional statistical methods[12].

Types of AI Models in Analytical Contexts

Machine Learning and Deep Learning

Machine learning (ML) models are broadly categorized by their learning approach. Supervised learning models, such as linear regression, support vector machines (SVMs), and random forests, are trained on input-output pairs to predict outcomes or classify data[15]. For example, a model might predict drug solubility based on molecular descriptors. Unsupervised learning, conversely, uncovers hidden patterns or structures in unlabeled data, often used for clustering or dimensionality reduction, like identifying distinct compound classes from spectroscopic data[13]. Deep Learning (DL), a specialized branch of ML, employs artificial neural networks (ANNs) with multiple layers to progressively extract higher-level features from raw input[7, 8]. Convolutional Neural Networks (CNNs) excel in image and spectral data analysis, processing raw signals for feature extraction and pattern recognition[17, 18]. Recurrent Neural Networks (RNNs) are adept at handling sequential data, such as time-series data from process monitoring[16]. The hierarchical learning capabilities of DL models allow them to identify complex relationships within analytical data, leading to enhanced predictive accuracy and automation in tasks like spectral deconvolution and impurity profiling[19].

Natural Language Processing and Other AI Paradigms

Beyond traditional machine learning and deep learning, other AI paradigms contribute to pharmaceutical analysis. Natural Language Processing (NLP) focuses on enabling computers to understand, interpret, and generate human language[5]. In analytical contexts, NLP can extract valuable information from unstructured text data, such as scientific literature, patent databases, and lab reports, to identify relevant analytical methods, experimental conditions, or reported impurity profiles. This can accelerate method development and literature review processes. Expert systems, rooted in symbolic AI, capture human expertise in a rule-based format, offering decision support for complex analytical problems, such as troubleshooting instrument malfunctions or guiding method optimization[20, 21]. Fuzzy logic systems, which handle uncertainty and imprecision, are useful in situations where analytical parameters are not sharply defined, such as in automated drug delivery systems where patient needs are variable[22]. Evolutionary computation, including genetic algorithms, can optimize complex analytical parameters by mimicking natural selection, finding optimal solutions for method development or calibration model generation. These diverse AI approaches collectively expand the capabilities of analytical chemists, offering tools for knowledge extraction, decision support, and optimization.

Relevance of AI for Pharmaceutical Analytics

AI's relevance for pharmaceutical analytics stems from its capacity to address several inherent challenges associated with traditional methods, including data volume, complexity, and the need for high-throughput analysis. The pharmaceutical industry generates vast amounts of data from research, development, and manufacturing processes, often exceeding human analytical capabilities[1, 23]. AI algorithms can process and derive insights from these large datasets efficiently, identifying subtle patterns and correlations that are otherwise undetectable[4]. This facilitates improved accuracy in qualitative and quantitative analysis, accelerated method development, and enhanced predictive capabilities for stability and degradation studies[10]. AI enables automation of repetitive tasks, reducing manual errors and increasing laboratory throughput. Furthermore, AI's ability to learn from historical data allows for continuous improvement in analytical models, leading to more robust and reliable results over time[24]. The integration of AI into pharmaceutical analytics consequently provides a strategic advantage, supporting faster decision-making, cost reduction, and ultimately, the more efficient delivery of pharmaceutical products[1].

Comparative Assessment: Traditional versus AI-Enhanced Analytical Approaches

Limitations of Conventional Analytical Methods

Traditional pharmaceutical analytical methods, while foundational and highly reliable, exhibit certain limitations that can impede efficiency and introduce variability. Manual data processing and interpretation are time-consuming and susceptible to human error, particularly for complex chromatograms or spectra with overlapping peaks[25]. Method development and optimization often involve extensive experimental iterations, a process that is resource-intensive and slow. The analysis of complex matrices, such as biological samples or multi-component drug formulations, can present significant challenges for selectivity and sensitivity with conventional techniques. Furthermore, traditional methods typically require highly skilled personnel for operation, calibration, and maintenance, contributing to operational costs. The ability to identify subtle patterns in large datasets, crucial for impurity profiling or stability prediction, is also constrained by human cognitive limits and the computational power of standard software. These limitations collectively highlight the need for advanced tools that can augment human capabilities and streamline analytical workflows.

Advantages and Transformative Potential of AI Integration

The integration of AI into pharmaceutical analytical techniques offers substantial advantages, addressing many limitations inherent in conventional methods. AI-enhanced approaches improve analytical speed and throughput by automating data acquisition, processing, and interpretation, thereby reducing manual labor and human error[10]. The predictive capabilities of AI models enable more efficient method development and optimization, minimizing trial-and-error experimentation. AI algorithms excel at discerning subtle patterns and anomalies in large, complex datasets, which significantly enhances the accuracy of qualitative and quantitative analyses, particularly in impurity detection and structural elucidation[15]. For example, AI can identify degradation products or characterize unknown compounds with higher precision than traditional peak-picking or library-matching methods. The continuous learning capabilities of AI models allow analytical systems to adapt and improve over time, leading to more robust and reliable results. This transformative potential extends to real-time monitoring and control in manufacturing, enabling proactive adjustments and continuous process optimization. Ultimately, AI integration translates into faster development cycles, reduced analytical costs, and enhanced overall product quality and safety.

Case Studies and Efficiency Comparisons

Numerous case studies illustrate the enhanced efficiency and capabilities conferred by AI integration in pharmaceutical analysis. In High-Performance Liquid Chromatography (HPLC), AI algorithms have been applied to optimize separation conditions, predict retention times, and automate peak deconvolution, significantly reducing method development time from weeks to days[25]. For instance, deep learning models can accurately identify and quantify components in complex mixtures even with overlapping peaks, a task often challenging for traditional integration software. In Mass Spectrometry (MS), AI-driven approaches have improved the speed and accuracy of molecular identification by automating spectral interpretation and facilitating metabolite profiling, particularly in non-targeted analyses (9). Studies demonstrate that AI-enhanced MS workflows can process large metabolomics datasets orders of magnitude faster than manual or semi-automated methods. Nuclear Magnetic Resonance (NMR) spectroscopy benefits from AI for automated spectral assignment and structural elucidation, accelerating the characterization of novel drug candidates and impurities[2]. Comparative analyses often show that AI-assisted processes yield higher data consistency, reduced inter-operator variability, and considerable time savings, freeing up expert analysts for more complex problem-solving. This translates directly into improved laboratory productivity and accelerated timelines for drug development and quality assurance.

AI Applications in Core Pharmaceutical Analytical Techniques

High-Performance Liquid Chromatography (HPLC)

High-Performance Liquid Chromatography (HPLC) is a cornerstone technique for separating, identifying, and quantifying components in pharmaceutical samples. The complexity of chromatographic data, often involving numerous peaks, baselines shifts, and noise, presents a rich area for AI application. AI can enhance various stages of the HPLC workflow, from method development and optimization to data processing and interpretation. Machine learning algorithms can predict optimal mobile phase compositions, column types, and temperature settings based on desired separation criteria and compound properties, minimizing the extensive experimental trials typically required. Furthermore, AI models can automate the detection and integration of peaks, even in challenging chromatograms, improving the consistency and accuracy of quantitative results. The ability of AI to learn from vast datasets of past separations facilitates the development of robust and transferable analytical methods, thereby accelerating the overall analytical process and ensuring higher data quality[25].

AI-Driven Signal Processing and Peak Identification

AI algorithms significantly advance signal processing and peak identification in HPLC. Traditional methods often rely on predefined thresholds and algorithms that may struggle with complex chromatograms exhibiting co-elution, noise, or baseline drift. Deep learning models, particularly Convolutional Neural Networks (CNNs), can analyze raw chromatographic signals to identify and deconvolve overlapping peaks with high fidelity, even in challenging matrices[18]. These networks learn intricate features from vast datasets of chromatograms, enabling them to distinguish true peaks from noise and artifacts more accurately than conventional peak detection algorithms. AI-driven baseline correction techniques can adapt to varying baseline profiles, providing more accurate peak integration. The automation provided by AI minimizes subjective human intervention, leading to more consistent and reproducible peak identification and integration, which is critical for quantitative analysis and impurity profiling in pharmaceutical quality control. This enhances the reliability of analytical results and accelerates data turnaround.

Automated Data Interpretation and Quantification

AI plays a transformative role in automating data interpretation and quantification in HPLC. Once peaks are identified and integrated, AI models can automatically associate them with known compounds by comparing retention times and spectral data (e.g., from UV-Vis detectors) against comprehensive databases. For quantification, machine learning algorithms can build sophisticated calibration models that account for non-linearities and matrix effects, often outperforming traditional linear regression approaches. Beyond mere quantification, AI can interpret complex chromatographic profiles to identify and quantify impurities, degradation products, and excipients in formulations. This is particularly valuable for stability studies and quality assurance, where comprehensive profiling is essential. Automated reporting features, powered by AI, can generate compliance-ready data summaries and reports, drastically reducing the manual effort and potential for transcription errors. The comprehensive automation from raw signal to final report accelerates analytical throughput and ensures consistent, high-quality data for decision-making in pharmaceutical development and manufacturing.

Mass Spectrometry (MS)

Mass Spectrometry (MS) is a powerful analytical technique providing detailed information on the molecular weight and structure of compounds, crucial for drug discovery, metabolism studies, and quality control. The high dimensionality and complexity of MS data, especially in untargeted analyses, make it an ideal candidate for AI integration. AI algorithms can manage the vast amounts of spectral data generated by modern MS instruments, extracting meaningful biological and chemical insights. From identifying novel compounds and metabolites to quantifying trace impurities, AI enhances the capabilities of MS across various pharmaceutical applications. AI-driven workflows improve data preprocessing, such as noise reduction and baseline correction, and facilitate advanced data analysis, including molecular formula generation and structural elucidation. This integration significantly accelerates the interpretation of complex mass spectra, enabling faster decision-making in research and development processes.

Molecular Pattern Recognition

AI excels at molecular pattern recognition within Mass Spectrometry data, a capability that significantly enhances compound identification and characterization. Deep learning models, especially those designed for spectral analysis, can learn complex relationships between mass spectral features (e.g., accurate mass, isotopic patterns, fragmentation ions) and molecular structures[9]. This allows for the rapid and accurate identification of known compounds by matching their spectral fingerprints against extensive databases. Furthermore, AI can identify novel or unexpected compounds by recognizing characteristic fragmentation patterns even without a direct database match, inferring structural motifs. This is particularly valuable in impurity profiling and unknown substance identification, where traditional methods might struggle with fragmented or low-abundance signals. Machine learning classifiers can differentiate between similar compounds or isomers based on subtle spectral variations, providing a higher level of discrimination than manual interpretation. This pattern recognition capability streamlines the laborious process of MS data analysis, yielding more comprehensive and reliable results.

AI-Facilitated Metabolite Profiling

AI significantly enhances metabolite profiling using Mass Spectrometry, a critical aspect of drug metabolism and pharmacokinetics studies. Metabolite profiling involves the identification and quantification of small molecules in biological samples, providing insights into drug efficacy, toxicity, and disease states. The sheer volume and complexity of metabolomics data, often involving thousands of features, make manual analysis impractical. AI algorithms, particularly those for unsupervised learning and dimensionality reduction, can identify distinct metabolite patterns indicative of drug exposure or disease progression[13]. Machine learning models can predict metabolic pathways, identify biomarkers, and correlate metabolite changes with specific physiological responses. Deep learning approaches can process raw MS data to automatically detect and quantify metabolites, even at low concentrations, and distinguish them from endogenous compounds or matrix interferences. This AI-facilitated approach accelerates the discovery of novel drug metabolites, streamlines the analysis of complex biological samples, and provides a more comprehensive understanding of drug disposition within biological systems.

Nuclear Magnetic Resonance (NMR) Spectroscopy

Nuclear Magnetic Resonance (NMR) spectroscopy provides invaluable, non-destructive structural information about molecules, making it indispensable in pharmaceutical research for drug structure elucidation, purity assessment, and formulation analysis. The interpretation of NMR spectra, especially for complex molecules or mixtures, can be time-consuming and requires significant expertise. AI integration offers solutions to automate and enhance various aspects of NMR data analysis, from spectral deconvolution to automated compound identification. AI algorithms can handle the high data density and subtle chemical shift variations inherent in NMR spectra, enabling faster and more accurate structural assignments. This facilitates the rapid characterization of new chemical entities, identification of impurities, and confirmation of active pharmaceutical ingredients. The ability of AI to learn from large spectral databases and chemical structure information streamlines the analytical workflow, increasing efficiency and reducing the manual burden on expert spectroscopists.

Spectral Deconvolution and Structural Elucidation

AI significantly advances spectral deconvolution and structural elucidation in NMR spectroscopy. Complex NMR spectra often feature overlapping signals, especially in mixtures or for large molecules, complicating peak assignment and integration. AI algorithms, including machine learning and deep learning, can deconvolve these overlapping signals, isolating individual component spectra and improving quantitative accuracy. For structural elucidation, AI models can learn the correlation between molecular substructures and their characteristic NMR chemical shifts and coupling patterns[2]. This allows AI to predict chemical structures from experimental NMR data or to verify proposed structures by simulating their spectra and comparing them to observed data. Expert systems and knowledge-based AI approaches can integrate various spectroscopic data (e.g., 1D and 2D NMR, MS, IR) to generate plausible molecular structures, dramatically reducing the time required for unknown compound identification. This automation of complex spectral interpretation accelerates the characterization of drug candidates and impurities during pharmaceutical development.

Automated Compound Identification

Automated compound identification using AI in NMR spectroscopy revolutionizes the characterization workflow in pharmaceutical laboratories. AI systems leverage extensive databases of known NMR spectra and corresponding chemical structures to perform rapid and accurate compound identification. By comparing experimental NMR spectra to these libraries, machine learning algorithms can identify the most probable compound matches, even with incomplete or noisy data. This extends beyond simple library matching; AI can account for variations due to solvent, temperature, or concentration effects, improving identification robustness. For novel compounds, AI can generate hypothetical structures and predict their NMR spectra for comparison, iteratively refining the structural assignment. This capability is particularly beneficial for high-throughput screening, quality control of raw materials and finished products, and the rapid characterization of impurities or degradation products. The automation provided by AI reduces the reliance on manual expert interpretation, enhances consistency, and accelerates the overall process of compound identification, critical for maintaining stringent quality standards in pharmaceutical manufacturing.

Infrared (IR) and Raman Spectroscopy

Infrared (IR) and Raman spectroscopy are vibrational spectroscopic techniques that provide unique chemical fingerprints of molecules, making them valuable for material identification, polymorph screening, and quality control in pharmaceuticals. The rich spectral information contained in IR and Raman data often requires sophisticated chemometric methods for interpretation, especially for complex mixtures or subtle structural differences. AI significantly enhances the analytical power of these techniques by improving signal processing, feature extraction, and multivariate data analysis. AI algorithms can handle large datasets of spectra, enabling rapid classification and quantification of components. This integration facilitates faster and more accurate identification of raw materials, detection of counterfeit drugs, and monitoring of critical process parameters in real-time. By automating spectral interpretation and pattern recognition, AI makes IR and Raman spectroscopy more accessible and powerful for routine pharmaceutical analysis.

Multivariate Analysis for Component Discrimination

AI substantially improves multivariate analysis for component discrimination in IR and Raman spectroscopy. Pharmaceutical applications frequently involve distinguishing between active pharmaceutical ingredients (APIs), excipients, different polymorphs, or identifying contaminants in a mixture. Traditional multivariate methods like Principal Component Analysis (PCA) and Partial Least Squares (PLS) are often used, but AI algorithms can augment their capabilities or provide more advanced pattern recognition. Machine learning classifiers, such as Support Vector Machines (SVMs) or Artificial Neural Networks (ANNs), can be trained on spectral datasets to accurately discriminate between different components or product variations[15]. Deep learning, particularly CNNs, can directly process raw spectral data to extract highly discriminatory features, leading to superior classification performance even for subtle spectral differences. This enables rapid and reliable identification of raw materials, polymorphs, and counterfeit products, which is essential for ensuring product quality and authenticity throughout the supply chain.

AI-Based Noise Reduction and Feature Extraction

AI plays a critical role in enhancing the quality of IR and Raman spectral data through advanced noise reduction and feature extraction techniques. Raw vibrational spectra are often affected by noise, fluorescence (especially in Raman), and baseline variations, which can obscure important spectral features and compromise quantitative analysis. AI algorithms, including various filtering and denoising techniques based on machine learning, can effectively remove unwanted signal components while preserving the analytical information. Deep learning models can be trained to recognize and remove noise patterns, leading to cleaner, more interpretable spectra. For feature extraction, AI goes beyond simple peak picking, employing algorithms that identify the most relevant spectral features or combinations of features that are highly correlated with specific chemical properties or concentrations. This advanced feature engineering, performed automatically by AI, improves the robustness and predictive power of subsequent quantitative models and classification tasks. The result is higher quality data that yields more accurate and reliable analytical outcomes.

UV-Vis Spectrophotometry

UV-Vis spectrophotometry is a widely used, simple, and cost-effective analytical technique for quantifying compounds that absorb ultraviolet or visible light. It is commonly applied in pharmaceutical quality control for assaying active ingredients, dissolution testing, and content uniformity measurements. Despite its simplicity, challenges arise in analyzing complex mixtures where spectral overlap occurs, or when dealing with matrix effects. AI offers significant enhancements to UV-Vis spectrophotometry, particularly in improving calibration models and enabling more sophisticated predictive analytics for concentration estimation. AI algorithms can manage the multivariate nature of spectral data, extract relevant information from overlapping spectra, and build robust models that account for interferences, thereby extending the utility and accuracy of UV-Vis methods beyond traditional Beer-Lambert law applications. This integration streamlines routine quality control analyses and provides more reliable quantitative results.

AI-Assisted Calibration Modeling

AI significantly enhances calibration modeling in UV-Vis spectrophotometry, particularly for complex samples. Traditional UV-Vis quantification often relies on Beer-Lambert law, which assumes linearity and no spectral interferences. However, in real-world pharmaceutical samples, matrix effects or co-eluting compounds can lead to non-linear responses and overlapping spectra. AI-assisted calibration modeling employs machine learning algorithms, such as Partial Least Squares (PLS) regression, Principal Component Regression (PCR), or Artificial Neural Networks (ANNs), to build robust multivariate calibration models. These models can simultaneously analyze the full spectrum, accounting for spectral overlap and matrix effects, to accurately quantify multiple components in a mixture. ANNs, with their ability to model non-linear relationships, can handle complex spectral data where traditional linear models fail. This leads to more accurate and reliable concentration estimations, reducing the need for extensive sample preparation or chromatographic separation prior to UV-Vis analysis.

Predictive Analytics for Concentration Estimation

AI-driven predictive analytics revolutionize concentration estimation in UV-Vis spectrophotometry, moving beyond simple single-wavelength measurements. By leveraging machine learning models trained on large datasets of UV-Vis spectra and corresponding known concentrations, AI can accurately predict the concentration of analytes in unknown samples. This is particularly useful for rapid, high-throughput screening and in-line process monitoring. AI can also predict the stability or degradation of compounds over time by analyzing changes in their UV-Vis spectra, providing early warnings for potential quality issues. Furthermore, AI can be used to predict the presence of impurities or contaminants based on deviations from expected spectral profiles. This predictive capability transforms UV-Vis spectrophotometry from a purely quantitative tool into a more comprehensive analytical platform, providing actionable insights for quality control, stability assessment, and process optimization with greater speed and accuracy.

Artificial Intelligence in Quality Control and Process Analytical Technology (PAT)

Real-Time Monitoring and Control via AI

AI plays a transformative role in enabling real-time monitoring and control within pharmaceutical manufacturing, especially through Process Analytical Technology (PAT) initiatives. PAT aims to design, analyze, and control manufacturing processes through timely measurements of critical quality and performance attributes of raw and in-process materials, and processes. AI algorithms, particularly machine learning models, can process high-frequency data streams from various in-line and at-line sensors (e.g., spectroscopic probes, particle size analyzers)[24]. This real-time data analysis allows for continuous assessment of product quality and process state. For instance, AI can monitor crystallization processes, granulation, or tablet compression, identifying deviations from optimal parameters instantaneously. Predictive models can anticipate potential issues before they manifest, triggering automated adjustments to process variables, thereby maintaining product quality and consistency. This capability minimizes batch-to-batch variability, reduces waste, and enhances overall manufacturing efficiency, moving towards a more proactive and controlled production environment.

Fault Detection and Process Optimization Algorithms

AI algorithms are highly effective for fault detection and process optimization in pharmaceutical manufacturing. By analyzing historical and real-time process data, machine learning models can learn the normal operating parameters and patterns of a manufacturing process. Any significant deviation from these learned patterns can be flagged as a potential fault, allowing for early detection of equipment malfunctions, material inconsistencies, or process anomalies. This proactive fault detection minimizes downtime, prevents batch failures, and ensures continuous operation within desired quality specifications. For process optimization, AI algorithms, including evolutionary computation and reinforcement learning, can explore vast parameter spaces to identify optimal operating conditions that maximize yield, improve product quality, or reduce energy consumption. These algorithms iteratively learn from the outcomes of different parameter settings, converging on highly efficient process configurations. The application of AI in this context leads to more robust, efficient, and cost-effective pharmaceutical production processes, contributing to overall operational excellence.

Role of AI in Quality by Design (QbD) Implementation

AI significantly supports the implementation of Quality by Design (QbD) principles in pharmaceutical manufacturing. QbD is a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. AI contributes to QbD by facilitating comprehensive process understanding and robust control strategies. During the development phase, AI can analyze experimental data to identify critical process parameters (CPPs) and critical material attributes (CMAs) that influence critical quality attributes (CQAs) of the drug product. Machine learning models can build predictive relationships between these parameters, allowing for the establishment of a design space where desired product quality is assured. In the manufacturing phase, AI-driven PAT tools enable real-time monitoring and adaptive control within this design space, ensuring that the process consistently operates within acceptable limits. This proactive approach to quality management, heavily augmented by AI, reduces the need for extensive end-product testing and fosters a culture of continuous improvement and inherent product quality.

Chemometrics and Multivariate Data Analysis: AI Approaches

Pattern Recognition and Data Reduction Techniques

Chemometrics, the application of mathematical and statistical methods to chemical data, forms a natural synergy with AI, particularly in pattern recognition and data reduction. Analytical techniques like spectroscopy and chromatography generate high-dimensional datasets where each sample produces numerous data points (e.g., thousands of spectral channels or time points). Manual interpretation of such complex data is often impractical. AI-driven pattern recognition techniques, including Principal Component Analysis (PCA) and various clustering algorithms, can identify inherent structures, groupings, or outliers within these datasets[13]. PCA, for instance, reduces the dimensionality of data while retaining most of the variance, allowing for visualization of patterns and relationships that would otherwise be obscured. For data reduction, AI algorithms can identify redundant variables or features, simplify models and improve computational efficiency without significant loss of information. This enables more efficient data exploration, classification, and quantitative analysis, especially in complex analytical scenarios such as distinguishing between different drug formulations or identifying unknown impurities within a large dataset.

PCA, PLS, and Artificial Neural Network Applications

Principal Component Analysis (PCA), Partial Least Squares (PLS) regression, and Artificial Neural Networks (ANNs) are prominent AI and chemometric tools extensively applied in pharmaceutical analysis. PCA is primarily used for exploratory data analysis, identifying patterns, outliers, and underlying relationships in multivariate datasets, such as spectroscopic fingerprints of different raw materials[13]. PLS is a powerful regression method for building predictive models between spectroscopic data (X variables) and chemical properties or concentrations (Y variables), particularly useful when X variables are highly correlated, as often seen in spectral data. This enables accurate quantification of components in complex mixtures. ANNs, as a subset of deep learning, provide a non-linear modeling capability that can capture intricate relationships in data that linear methods like PCA and PLS might miss[11, 10, 26]. ANNs are applied for classification (e.g., identifying drug polymorphs), quantitative prediction (e.g., drug content), and even spectral deconvolution. The synergistic application of these techniques allows for comprehensive data interpretation, robust model building, and enhanced analytical precision across diverse pharmaceutical applications, from quality control to process optimization.

Software Tools: SIMCA, MATLAB, and Emerging Platforms

The practical application of AI and chemometrics in pharmaceutical analysis relies heavily on specialized software tools. SIMCA (Sartorius Stedim Biotech), a widely used chemometrics software, offers robust capabilities for multivariate data analysis, including PCA, PLS, and discriminant analysis, enabling users to build predictive models and classify samples based on analytical data. MATLAB (MathWorks) provides a versatile programming environment with extensive toolboxes for machine learning, deep learning, and statistical analysis, allowing researchers to develop custom AI algorithms and integrate them with analytical data. Its flexibility makes it a preferred platform for developing novel analytical methodologies and complex AI models. Beyond these established tools, emerging platforms and open-source libraries, such as Python with scikit-learn, TensorFlow, and PyTorch, are gaining traction. These platforms offer powerful deep learning frameworks and a vast ecosystem of machine learning algorithms, facilitating the development of highly sophisticated AI solutions for spectral interpretation, chromatographic data analysis, and process modeling. The accessibility and continuous development of these tools enable a broader adoption of AI-driven analytical strategies in the pharmaceutical industry.

AI-Driven Impurity Profiling and Stability Analysis

Degradation Prediction and Impurity Identification Models

AI models significantly enhance degradation prediction and impurity identification in pharmaceutical products. Drug degradation pathways are often complex, influenced by factors like temperature, humidity, light, and pH. Traditional stability studies involve extensive experimental work to establish degradation kinetics and identify impurities. AI algorithms, particularly machine learning and deep learning, can build predictive models that correlate forced degradation study data with potential degradation products and their formation rates. By analyzing spectroscopic (e.g., UV-Vis, IR, NMR) and chromatographic (e.g., HPLC-UV, LC-MS) data, AI can identify known and novel impurities based on their unique spectral or chromatographic fingerprints, even at low concentrations. This capability reduces the time and resources required for impurity characterization and provides early insights into potential stability issues, accelerating the development of stable formulations. AI models can also predict the likelihood of specific degradation pathways under various storage conditions, enabling proactive risk mitigation.

Shelf-Life Estimation Using Machine Learning

Machine learning provides advanced capabilities for estimating the shelf-life of pharmaceutical products, moving beyond traditional kinetic models. Conventional methods often rely on Arrhenius kinetics derived from accelerated stability studies, which may not always accurately reflect real-time degradation under varied storage conditions. Machine learning models, trained on comprehensive stability data that include various environmental factors (temperature, humidity, light exposure) and formulation variables, can build more accurate and robust predictive models for shelf-life. These models can identify non-linear degradation patterns and complex interactions between factors that influence product stability. By incorporating real-time monitoring data from storage facilities, AI can continuously refine shelf-life predictions, offering dynamic estimates that adapt to actual storage conditions. This machine learning-driven approach enables more precise shelf-life assignments, reduces the need for lengthy real-time stability studies, and supports more efficient inventory management, minimizing product waste due to expiry.

Predictive Analytics in Forced Degradation Studies

Predictive analytics, powered by AI, transforms forced degradation studies in pharmaceutical development. Forced degradation studies are essential for understanding the intrinsic stability of a drug substance and product, elucidating degradation pathways, and identifying potential degradation products. Traditionally, these studies involve exposing drug substances to harsh conditions (e.g., high temperature, extreme pH, oxidation) and then analyzing the samples using various analytical techniques. AI models can predict the outcome of forced degradation studies based on molecular structure and historical data, guiding the selection of optimal stress conditions and analytical methods. Machine learning can analyze the resulting complex analytical data (e.g., LC-MS chromatograms with hundreds of peaks) to rapidly identify and characterize degradation products, even those present at very low levels. This predictive capability accelerates the identification of potential impurities, streamlines the development of stability-indicating methods, and provides a deeper understanding of a drug's stability profile earlier in the development cycle, ultimately contributing to a more robust and safer product.

Regulatory Considerations and Validation Strategies for AI Models

Compliance with FDA, EMA, and ICH Guidelines

The integration of AI into pharmaceutical analytical techniques necessitates careful consideration of regulatory compliance, particularly with guidelines from agencies such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). These bodies emphasize data integrity, traceability, and the validation of analytical methods to ensure product quality and patient safety. For AI models, compliance extends to demonstrating that the model is fit for its intended purpose, provides reliable and reproducible results, and operates within a controlled environment. Key aspects include ensuring data quality and provenance, validating the algorithms, managing model version control, and maintaining comprehensive documentation of the model's development, training, and performance. Transparency in model decision-making, though challenging for complex deep learning models, is increasingly important for regulatory scrutiny. Adherence to these guidelines ensures that AI-driven analytical tools are trustworthy and acceptable for use in regulated pharmaceutical environments.

Validation Strategies for AI-Based Analytical Tools

Validation strategies for AI-based analytical tools must be robust and comprehensive, adapting traditional analytical method validation principles to the unique characteristics of AI models. Key elements of validation include establishing the model's accuracy, precision, linearity, range, specificity, detection limit, and quantitation limit. However, for AI, additional considerations arise. Model performance must be evaluated on independent, unseen datasets to demonstrate generalizability and prevent overfitting. Cross-validation techniques, such as k-fold validation, are crucial during model development. Sensitivity analysis can assess how changes in input data affect model output. Interpretability and explainability of AI models are increasingly important, especially for regulatory acceptance; understanding why a model makes a particular prediction enhances trust and facilitates troubleshooting. Ongoing monitoring of model performance in a real-world setting, coupled with periodic re-validation or re-training, is essential to ensure continued fitness for purpose as data characteristics or process conditions evolve. Documentation of data lineage, model architecture, training parameters, and performance metrics is paramount for auditability.

Ethical, Data Integrity, and Transparency Issues

The deployment of AI in pharmaceutical analytics raises significant ethical, data integrity, and transparency issues. Ethically, concerns exist regarding potential biases encoded in training data, which could lead to discriminatory outcomes or inaccurate analyses if not carefully managed. Ensuring fairness and equity in AI applications is a growing area of focus. Data integrity is paramount; AI models are only as reliable as the data they are trained on. Issues such as data incompleteness, inaccuracies, or malicious manipulation can severely compromise model performance and the validity of analytical results. Robust data governance, security protocols, and audit trails are essential to maintain data integrity throughout the AI lifecycle. Transparency, or the ability to understand how an AI model arrives at a particular conclusion, presents a substantial challenge, particularly for complex deep learning models often termed "black boxes"[27]. Lack of transparency can hinder regulatory acceptance, make troubleshooting difficult, and erode trust in AI-driven decisions. Developing explainable AI (XAI) techniques to provide insights into model reasoning is an active research area to address these transparency concerns, aiming to bridge the gap between AI's predictive power and human understanding and trust.

Challenges, Limitations, and Integration Barriers

Data Quality, Standardization, and Curation Issues

A primary challenge in implementing AI in pharmaceutical analytical techniques stems from issues related to data quality, standardization, and curation. AI models are highly dependent on large volumes of high-quality, well-structured, and representative data for effective training and validation[28]. However, analytical data in pharmaceutical settings are often heterogeneous, residing in disparate formats across different instruments, laboratories, and legacy systems. Inconsistencies in data acquisition protocols, calibration procedures, and reporting standards can introduce significant variability and bias. Lack of proper data annotation and metadata can further hinder AI model development. Curation, the process of organizing and maintaining data for optimal use, is laborious and resource-intensive, yet crucial for building robust AI models. Overcoming these data-related challenges requires significant investment in data infrastructure, standardization efforts (e.g., common data models, ontologies), and dedicated data science teams to ensure the availability of clean, reliable data for AI applications.

Model Interpretability, Transparency, and Trustworthiness

Model interpretability and transparency present significant hurdles for the widespread adoption of AI in pharmaceutical analytical settings, particularly in regulated environments. While complex AI models, especially deep neural networks, often achieve superior predictive performance, their internal decision-making processes can be opaque, leading to "black box" concerns[27]. This lack of transparency can hinder trust among analytical chemists and regulatory bodies, who require a clear understanding of why a model yields a specific result, especially when it concerns product quality or patient safety. Explaining the reasoning behind an AI-driven peak identification or impurity quantification is crucial for auditability and troubleshooting. Efforts in Explainable AI (XAI) are addressing this by developing methods to render AI models more transparent, such as feature importance analysis or localized explanations. However, achieving full interpretability without compromising model performance remains an active research area. Building trustworthiness also involves rigorous validation, continuous monitoring, and clear communication of model limitations.

Integration with Existing Laboratory Workflows

Integrating AI-driven analytical tools into existing pharmaceutical laboratory workflows poses a considerable practical barrier. Pharmaceutical laboratories often operate with established, validated procedures and legacy instrumentation, making rapid adoption of new technologies challenging. The transition requires significant changes in laboratory information management systems (LIMS), data handling protocols, and personnel training. Interoperability between AI software, analytical instruments, and existing data infrastructure is often complex, demanding custom development and validation. Resistance to change from personnel accustomed to traditional methods can also impede adoption, underscoring the need for comprehensive training and demonstrations of AI's tangible benefits. Furthermore, the cost of implementing new AI hardware and software, coupled with the ongoing maintenance and validation of AI models, can be substantial. Successful integration requires a phased approach, careful planning, and a commitment to investing in both technology and human capital to ensure a smooth transition and maximize the benefits of AI in the analytical laboratory.

Future Perspectives and Emerging Opportunities

AI in Personalized Medicine and Real-Time Release Testing (RTRT)

AI is set to play a transformative role in personalized medicine and Real-Time Release Testing (RTRT) within the pharmaceutical landscape. In personalized medicine, AI can analyze individual patient data, including genomic, proteomic, and metabolomic profiles, alongside drug response data, to predict optimal drug dosages and identify specific patient cohorts that will benefit most from particular therapies[29]. AI-enhanced analytical techniques will enable rapid, high-throughput characterization of patient samples, facilitating the development and monitoring of customized treatments. For RTRT, which allows for the release of individual batches of product based on real-time process monitoring and control rather than extensive end-product testing, AI will be critical. AI algorithms can continuously analyze in-line process data from PAT sensors, predicting product quality attributes with high confidence[23]. This enables instantaneous quality assessment and product release, significantly accelerating manufacturing cycles, reducing inventory, and ensuring consistent product quality tailored to individual needs or precise process conditions. The synergy between AI and these advanced manufacturing paradigms represents a significant step towards more agile and patient-centric pharmaceutical production.

Integration with Digital Twins and Internet of Things (IoT)

The future of pharmaceutical analytical techniques will be shaped by the deeper integration of AI with concepts such as Digital Twins and the Internet of Things (IoT). IoT involves networks of physical devices embedded with sensors, software, and other technologies to connect and exchange data with other devices and systems over the internet[23]. In analytical laboratories and manufacturing plants, IoT sensors can provide real-time data on instrument performance, environmental conditions, and process parameters. AI algorithms will process this vast stream of IoT data to monitor equipment health, predict maintenance needs, and optimize experimental conditions. Digital Twins are virtual replicas of physical assets, processes, or systems. An AI-powered digital twin of an analytical instrument or a manufacturing process can simulate its behavior, predict outcomes, and optimize operations in a virtual environment before changes are applied to the physical system. This integration allows for predictive maintenance, remote diagnostics, and continuous process optimization, leading to enhanced laboratory efficiency, reduced downtime, and improved analytical reliability. The combination of AI, IoT, and Digital Twins creates a highly interconnected and intelligent analytical ecosystem.

Towards Autonomous Laboratories: Potential Paradigms

The ultimate trajectory for AI in pharmaceutical analytical techniques points towards the realization of autonomous laboratories. In such a paradigm, AI systems would oversee the entire analytical workflow, from sample preparation and instrument operation to data analysis, interpretation, and reporting, with minimal human intervention. Robotic systems, guided by AI, could handle sample logistics and instrument loading. AI algorithms would continuously monitor analytical performance, perform self-calibration, and even troubleshoot minor issues. Machine learning models would adapt and optimize analytical methods in real-time based on incoming data and predefined quality targets. This vision extends to self-correcting processes in manufacturing, where AI detects deviations and autonomously adjusts parameters to maintain optimal conditions. While challenges related to safety, regulatory acceptance, and the complexity of unstructured tasks remain, the foundational elements for autonomous laboratories are being established. This transformative shift promises unprecedented levels of efficiency, reproducibility, and innovation in pharmaceutical research and development, accelerating the delivery of new medicines and ensuring their quality with minimal human oversight.

CONCLUSION

Summary of Key Findings

This review has elucidated the profound influence of Artificial Intelligence across the spectrum of modern pharmaceutical analytical techniques. Key findings indicate that AI, encompassing Machine Learning and Deep Learning, significantly enhances traditional methods by automating complex data processing, improving accuracy, and accelerating analytical workflows. Specific applications in High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), Nuclear Magnetic Resonance (NMR) spectroscopy, and Infrared (IR) and Raman spectroscopy demonstrate AI's capability to deconvolve complex signals, identify molecular patterns, and streamline structural elucidation. In quality control and Process Analytical Technology (PAT), AI facilitates real-time monitoring, fault detection, and process optimization, contributing to Quality by Design (QbD) implementation. Chemometrics, augmented by AI, provides advanced pattern recognition and data reduction techniques essential for multivariate analysis. Furthermore, AI-driven models enhance impurity profiling and stability analysis, enabling more accurate degradation prediction and shelf-life estimation. While challenges such as data quality, model interpretability, and integration barriers persist, strategic approaches to validation and adherence to regulatory guidelines are crucial for successful adoption.

Critical Insights on the Role and Potential of AI in Pharmaceutical Analysis

The critical insights derived from this review underscore AI's indispensable and expanding role in pharmaceutical analysis. AI transcends mere automation; it provides a computational framework for extracting deeper insights from complex, high-dimensional analytical data that would be intractable for traditional methods. Its predictive capabilities allow for proactive decision-making, moving from reactive problem-solving to preventative quality assurance and accelerated development cycles. The potential of AI extends to transforming pharmaceutical R&D and manufacturing into more efficient, cost-effective, and precise operations, ultimately contributing to faster drug discovery and enhanced product quality. Future integration with Digital Twins and IoT promises highly interconnected and intelligent analytical ecosystems. The ultimate progression towards autonomous laboratories represents a paradigm shift, where AI orchestrates entire analytical processes with minimal human intervention.

Realizing this potential hinges on continuous efforts in data standardization, developing explainable AI models to foster trust and regulatory acceptance, and strategic investment in infrastructure and human expertise. The ongoing evolution of AI tools and methodologies ensures its continued importance in shaping the future of pharmaceutical analytical science.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Kumar P. Artificial intelligence and its application in pharmaceutical medicines. International Journal of Research -GRANTHAALAYAH. 2019;7(9):382–385. Doi: https://doi.org/10.29121/granthaalayah.v7.i9.2019.623

2. Rodrigues G do V, Campos IP de A, Emerenciano V de P. Applications of artificial intelligence to structure determination of organic compounds. XX*. Determination of groups attached to the skeleton of natural products using ^{13}C nuclear magnetic resonance spectroscopy. Vol. 13, Journal of Spectroscopy. Wiley. 1997;13:191–200. Doi: https://doi.org/10.1155/1997/657194

3. Nagpal S. Big Data Analytics in Pharmaceutical Development. Journal of Pharmaceutical Research, 2016:15(3). Doi: https://doi.org/10.18579/jpcrkc/2016/15/3/103034

4. Chakraborty I, Choudhury A. Artificial Intelligence in Biological Data [Internet]. Vol. 07, Journal of Information Technology & Software Engineering, 2017;7(4):1-6 Doi: https://doi.org/10.4172/2165-7866.1000207

5. Kaur A, Mohammad Aslam A. Artificial Intelligence in Business. CSMFL Publications, 2020;1–38. Doi: https://doi.org/10.46679/isbn978819484834901

6. Abhinav GVKS, Naga Subrahmanyam S. Artificial Intelligence in Healthcare [Internet]. Vol. 9, Journal of Drug Delivery and Therapeutics, 2019;9(5-S):164–166. Doi: https://doi.org/10.22270/jddt.v9i5-s.3634

7. Sanas S, Patil S, Nimkarde ProfS. A Study on Artificial Intelligence International. Journal of Advanced Research in Computer and Communication Engineering, 2018;7(8):57–59. Doi: https://doi.org/10.17148/ijarcce.2018.7812

8. Isaacs D. Artificial intelligence in health care. Journal of Paediatrics and Child Health, 2020;56(10):1493-1495 Doi: https://doi.org/10.1111/jpc.14828

9. Hessler G, Baringhaus KH. Artificial Intelligence in Drug Design. Molecules, 2018;23(10):2520. Doi: https://doi.org/10.3390/molecules23102520

10. Sethuraman N. Artificial Intelligence: A New Paradigm for Pharmaceutical Applications in Formulations Development. Indian Journal of Pharmaceutical Education and Research, 2020;54(4):843–846. Doi: https://doi.org/10.5530/ijper.54.4.176.

11. Dojat M, Keravnou ET, Barahona P. Artificial Intelligence in Medicine. Lecture Notes in Computer Science. Springer Berlin Heidelberg; Paper presented: at 9th Conference on Artificial Intelligence in Medicine in Europe 2003. Protaras, Cyprus, Europe. Doi: https://doi.org/10.1007/b12009.

12. Kallem SR. Artificial Intelligence Algorithms. IOSR Journal of Computer Engineering, 2012;6(3):01–08. Doi: https://doi.org/10.9790/0661-0630108.

13. Visscher RMS, Feddermann-Demont N, Romano F, Straumann D, Bertolini G. Artificial intelligence for understanding concussion: Retrospective cluster analysis on the balance and vestibular diagnostic data of concussion patients. Public Library of Science, 2019;14(4):1-11. Doi: https://doi.org/10.1371/journal.pone.0214525.

14. Ernest P C. Artificial Intelligence Techniques, Machine Trading. Wiley; 2017. p. 83–117. Doi: https://doi.org/10.1002/9781119244066.ch4.

15. Talari ACS, Rehman S, Rehman IU. Advancing cancer diagnostics with artificial intelligence and spectroscopy: identifying chemical changes associated with breast cancer. Expert Review of Molecular Diagnostics, 2019;19(10):929–940. Doi: https://doi.org/10.1080/14737159.2019.1659727.

16. D'Agaro E. Artificial intelligence used in genome analysis studies [Internet]. Vol. 2, The EuroBiotech Journal, 2018;2(2):78–88. Doi: https://doi.org/10.2478/ebtj-2018-0012.

17. Tanabe, K., Ikeda, M., Hayashi, M., Matsuo, K., Yasaka, M., Machida, H., Shida, M., Katahira, T., Imanishi, T., Hirasawa, T., Sato, K., Yoshida, H., & Mikami, M. (2020). Comprehensive Serum Glycopeptide Spectra Analysis Combined with Artificial Intelligence (CSGSA-AI) to Diagnose Early-Stage Ovarian Cancer. Cancers, 2020;12(9):2373. Doi: https://doi.org/10.3390/cancers12092373.

18. ArtiWang P, Luo C, Pan F, Zhu Y. Analysis and Research of Artificial Intelligence Algorithms in GPS Data. IEEE Access. Institute of Electrical and Electronics Engineers (IEEE), 2020;1–1. Doi: https://doi.org/10.1109/access.2020.3021426.

19. Artificial Intelligence in Medicine. [Internet]. Vol. 98, Annals of Internal Medicine, 1983;98(6):1043–1043. Doi: https://doi.org/10.7326/0003-4819-98-6-1043_9.

20. Drew PJ, Monson JRT. Artificial intelligence for clinicians. Journal of the Royal Society of Medicine. SAGE Publications, 1999;92(3):108–109. Doi: https://doi.org/10.1177/014107689909200302.

21. Novak Jr, Gordon S. S, Robert F. P, Bruce W. K, Vipin C, Robert L. Artificial Intelligence Project. Defense Technical Information Center 1990; Doi: https://doi.org/10.21236/ada230793.

22. Barahona P, Stefanelli M, Wyatt J, editors. Artificial Intelligence in Medicine. Lecture Notes in Computer Science. Springer Berlin Heidelberg, 1995. Doi: https://doi.org/10.1007/3-540-60025-6.

23. Puaschunder JM, Feierabend D. Artificial Intelligence in the Healthcare Sector. SSRN Electronic Journal. Elsevier BV, 2019. Doi: https://doi.org/10.2139/ssrn.3469423.

24. Yan R, Nandi A, Wang P, Li W. Guest Editorial Special Issue on Smart Sensing and Artificial Intelligence-Enabled Data Analytics for Health Monitoring of Engineering Systems. IEEE Sensors Journal. Institute of Electrical and Electronics

Engineers (IEEE), 2020;20(15):8203–8203. Doi: https://doi.org/10.1109/jsen.2020.3000842.

25. Bainbridge MB, Webb JK. Artificial intelligence applied to the automatic analysis of absorption spectra. Objective measurement of the fine structure constant. Monthly Notices of the Royal Astronomical Society. Oxford University Press (OUP), 2017;468(2):1639-1670. Doi: https://doi.org/10.1093/mnras/stx179.

26. Ramesh A, Kambhampati C, Monson J, Drew P. Artificial intelligence in medicine. Annals of The Royal College of Surgeons of England. Royal College of Surgeons of England, 2004;86(5):334–338. Doi: https://doi.org/10.1308/147870804290.

27. Nensa F, Demircioglu A, Rischpler C. Artificial Intelligence in Nuclear Medicine. Journal of Nuclear Medicine. Society of Nuclear Medicine, 2019;60(2):29S-37S. Doi: https://doi.org/10.2967/jnumed.118.220590.

28. Schonemann PH. On artificial intelligence, Behavioral and Brain Sciences. Cambridge University Press (CUP), 1985;8:241–242. Doi: https://doi.org/10.1017/s0140525x0002063x.

29. Hamamoto R, Komatsu M, Takasawa K, Asada K, Kaneko S. Epigenetics Analysis and Integrated Analysis of Multiomics Data, Including Epigenetic Data, Using Artificial Intelligence in the Era of Precision Medicine. Biomolecules, 2019;10(1):1-21. Doi: https://doi.org/10.3390/biom10010062.

For any questions related to this article, please reach us at: globalresearchonline@rediffmail.com

New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com